FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	ROVAL
OMB Number:	3235-0287
Estimated average b	urden

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Royer Scott E.					2. Issuer Name and Ticker or Trading Symbol VACCINEX, INC. [VCNX]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner							
	Last) (First) (Middle) C/O VACCINEX, INC. 895 MOUNT HOPE AVENUE						3. Date of Earliest Transaction (Month/Day/Year) 12/27/2018										(give title hief Fina	ncial	Other (: below) Officer	specify	
(Street) ROCHESTER NY 14620 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)									Line)	. Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - Noi	n-Deriv	/ative	Se	curiti	es Ac	caui	ired. D	Dist	osed (of, or Be	enef	icially	Owned					
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				action	ction 2A. Dee			3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			or 5. Amou 4 and Securiti Benefic		unt of 6. ies Foially (D		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership			
										Code	,	Amount	(A) o	r P	. Transa		ted action(s) 3 and 4)			(Instr. 4)	
Common Stock 12/27/2					7/2018	2018				P		311 A		\$	4.15 ⁽¹⁾	3	311		D		
		Т	able II -										, or Ber ble sec			wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	ed Date,	4. Transac Code (Ir		5. Nu of Deriv Secu Acqu (A) o Disp of (D	5. Number 6. of E		ate Exerciration D nth/Day/	cisal ate	ole and 7. Title and Amo		ount 8.	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exer	e rcisable	Exp Date	piration ate	Title	Amo or Num of Sha	ber						
Stock option (right to buy)	\$13.6									(2)	02	/21/2028	Common Stock	25,	000		25,000)	D		

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$4.10 to \$4.20. The reporting person undertakes to provide to Vaccinex, Inc., any securityholder of Vaccinex, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number or shares purchased at each separate price.

2. This option initially vests in quarterly installments of 1,526 shares for each of four quarters beginning on May 21, 2018. The remainder vests in three equal annual installments beginning February 21, 2020.

Remarks:

/s/ Scott E. Royer

12/31/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.